ALS/Lt: A New Type 2 Diabetes Mouse Model Associated With Low Free Radical Scavenging Potential
- 1Department of Pediatrics, the University of Pittsburgh, Pittsburgh, Pennsylvania
- 2The Jackson Laboratory, Bar Harbor, Maine
- Address correspondence and reprint requests to Dr. Clayton E. Mathews, Diabetes Institute, 3460 5th Ave./Rangos Research Center, the University of Pittsburgh, Pittsburgh, PA 15213. E-mail: cem65{at}pitt.edu
Abstract
Outbred CD-1 mice carry a spectrum of genetic susceptibilities for obesity and type 2 diabetes. ALS is an inbred strain with low antioxidant defenses produced by inbreeding CD-1 mice, with selection for susceptibility to alloxan, a generator of highly reactive oxygen free radicals and a potent β-cell toxin. The objective of this study was to determine if the low ability to diffuse free radical stress would contribute to spontaneous type 2 diabetes development in alloxan-untreated males. Indeed, both hyperinsulinemia and impaired glucose tolerance developed spontaneously between 6 and 8 weeks of age in alloxan-untreated males. Further aging was accompanied by increases in body mass, progressively more severe hyperinsulinemia, and development of overt hyperglycemia. Transition from impaired glucose tolerance to overt hyperglycemia correlated with a decreased ratio of reduced to oxidized glutathione. Evidence that the increased oxidative burden elicited the type 2 diabetes syndrome was obtained by the systemic elevation of the antioxidative capacity through daily administration of R-lipoic acid. R-lipoic acid (30 mg/kg) prevented hyperglycemia, reduced insulin levels, and increased free radical scavenging potential. This mouse model with reduced ability to diffuse free radical stress is of obvious interest because free radical-mediated damage is implicated in the pathogenesis and complications of both type 1 and type 2 diabetes.
- AL, alloxan
- GSH, glutathione
- IGT, impaired glucose tolerance
- LA, R-lipoic acid
- ROS, reactive oxygen species
Footnotes
-
This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from Les Laboratoires Servier.
-
- Accepted April 7, 2003.
- Received March 27, 2003.
- DIABETES














